Abemaciclib plus fulvestrant in participants with HR+/HER2-advanced breast cancer: A pooled analysis of the endocrine therapy naive (EN) participants in MONARCH 2

Por: Trujillo, J, Gomez, M, Sohn, J, Im, Y, Wang, H, Cussac, A, Zhang, W, Haddad, N, Wasserstrom, H, van Hal, G and Sledge, G

---

Publicada: 1 sep 2021 Ahead of Print: 1 sep 2021

---

---

Filiaciones:
Trujillo, J:
 Fdn Rodolfo Padilla AC, Med Oncol, Leon Guanajuato, Mexico

Gomez, M:
 Grp Med Camino, Med Oncol, Mexico City, SC, Mexico

Sohn, J:
 Younsei Univ, Severence Hosp, Ctr Hlth, Seoul, South Korea

Im, Y:
 Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Dept Med, Seoul, South Korea

Wang, H:
 China Med Univ Hosp, Comprehens Breast Serv & Surg, Taichung, Taiwan

:
 Hosp Arnau Vilanova, Dept Med Oncol, Valencia, Spain

Zhang, W:
 Lilly Corp Ctr, LRL, Indianapolis, IN USA

Haddad, N:
 Lilly Corp Ctr, LRL, Indianapolis, IN USA

Wasserstrom, H:
 Lilly Corp Ctr, LRL, Indianapolis, IN USA

van Hal, G:
 Eli Lilly & Co, LRL, Utrecht, Netherlands

Sledge, G:
 Stanford Univ, Sch Med, Stanford, CA 94305 USA